RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery, today introduced mProveClinical™, a service offering that provides insight into a drug’s biochemical and physiological effects in first-in-human clinical trials. Combined with clinical observations and measurements, mProveClinical provides drug development organizations with key information on a subject’s response to a drug. This data enables more informed decisions to be made about the drug’s continued testing and positioning or, if required, offers guidance as to how it can be repositioned.
